Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||EML4 - ALK ALK A1200_G1201delinsW|
|Gene Variant Detail||
ALK A1200_G1201delinsW (unknown)
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - ALK ALK A1200_G1201delinsW||lung adenocarcinoma||predicted - resistant||Alectinib||Case Reports/Case Series||Actionable||In a clinical case study, post treatment biopsy analysis of a lung adenocarcinoma patient initially harboring EML4-ALK who developed progressive disease after 20 months of Alecensa (alectinib) treatment revealed acquisition of ALK A1200_G1201delinsW (PMID: 34548910).||34548910|
|EML4 - ALK ALK A1200_G1201delinsW||lung adenocarcinoma||predicted - sensitive||Brigatinib||Case Reports/Case Series||Actionable||In a clinical case study, a lung adenocarcinoma patient harboring EML4-ALK who developed resistance to Alecensa (alectinib) following acquisition of ALK A1200_G1201delinsW demonstrated symptom improvement and stable disease for 4 months with Alunbrig (brigatinib) treatment (PMID: 34548910).||34548910|